{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T11:04:01Z","timestamp":1791198241387,"version":"4.1.0"},"reference-count":43,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":["www.ahajournals.org"],"crossmark-restriction":true},"short-container-title":["Circ: Cardiovascular Quality and Outcomes"],"published-print":{"date-parts":[[2009,5]]},"abstract":"<jats:p>\n            <jats:bold>\n              <jats:italic>Background\u2014<\/jats:italic>\n            <\/jats:bold>\n            The cardiovascular safety of individual nonsteroidal antiinflammatory drugs (NSAIDs) is highly controversial, particularly in persons with serious coronary heart disease.\n          <\/jats:p>\n          <jats:p>\n            <jats:bold>\n              <jats:italic>Methods and Results\u2014<\/jats:italic>\n            <\/jats:bold>\n            We conducted a multisite retrospective cohort study of commonly used individual NSAIDs in Tennessee Medicaid, Saskatchewan Health, and United Kingdom General Practice Research databases. The cohort included 48566 patients recently hospitalized for myocardial infarction, revascularization, or unstable angina pectoris with more than 111000 person-years of follow-up. Naproxen users had the lowest adjusted rates of serious coronary heart disease (myocardial infarction, coronary heart disease death) and serious cardiovascular disease (myocardial infarction, stroke)\/death from any cause, with respective incidence rate ratios (relative to NSAID nonusers) of 0.88 (95% CI, 0.66 to 1.17) and 0.91 (0.78 to 1.06). Risk did not increase with doses \u22651000 mg. Relative to NSAID nonusers, serious coronary heart disease risk increased with short term (&lt;90 days) use for ibuprofen (1.67 [1.09 to 2.57]), diclofenac (1.86 [1.18 to 2.92]), celecoxib (1.37 [0.96 to 1.94]), and rofecoxib (1.46 [1.03 to 2.07]), but not for naproxen (0.88 [0.50 to 1.55]). Relative to naproxen, current users of diclofenac had increased risk of serious coronary heart disease (1.44 [0.96 to 2.15],\n            <jats:italic>P<\/jats:italic>\n            =0.076) and serious cardiovascular disease\/death (1.52 [1.22 to 1.89],\n            <jats:italic>P<\/jats:italic>\n            =0.0002), and those of ibuprofen had increased risk of the latter end point (1.25 [1.02 to 1.53],\n            <jats:italic>P<\/jats:italic>\n            =0.032). Compared to naproxen in doses \u22651000 mg, serious coronary heart disease incidence rate ratios were increased for rofecoxib &gt;25 mg (2.29 [1.24 to 4.22],\n            <jats:italic>P<\/jats:italic>\n            =0.008) and celecoxib &gt;200 mg (1.61 [1.01 to 2.57],\n            <jats:italic>P<\/jats:italic>\n            =0.046).\n          <\/jats:p>\n          <jats:p>\n            <jats:bold>\n              <jats:italic>Conclusions\u2014<\/jats:italic>\n            <\/jats:bold>\n            In patients recently hospitalized for serious coronary heart disease, naproxen had better cardiovascular safety than did diclofenac, ibuprofen, and higher doses of celecoxib and rofecoxib.\n          <\/jats:p>","DOI":"10.1161\/circoutcomes.108.805689","type":"journal-article","created":{"date-parts":[[2009,5,6]],"date-time":"2009-05-06T03:04:31Z","timestamp":1241579071000},"page":"155-163","update-policy":"https:\/\/doi.org\/10.1161\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":123,"title":["Cardiovascular Risks of Nonsteroidal Antiinflammatory Drugs in Patients After Hospitalization for Serious Coronary Heart Disease"],"prefix":"10.1161","volume":"2","author":[{"given":"Wayne A.","family":"Ray","sequence":"first","affiliation":[{"name":"From the Department of Preventive Medicine, Division of Pharmacoepidemiology (W.A.R., J.R.D.), Vanderbilt University School of Medicine; the Department of Medicine, Divisions of Rheumatology (C.C., C.M.S.), Cardiology (K.T.M.), and Clinical Pharmacology K.T.M., C.M.S.), and Department of Biostatistics (P.G.A.); and Geriatric Research, Education and Clinical Center (W.A.R.), Veterans\u2019 Administration Tennessee Valley Health Care System, Nashville, Tenn; Research Triangle Institute Health Solutions (C..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Varas-Lorenzo","sequence":"additional","affiliation":[{"name":"From the Department of Preventive Medicine, Division of Pharmacoepidemiology (W.A.R., J.R.D.), Vanderbilt University School of Medicine; the Department of Medicine, Divisions of Rheumatology (C.C., C.M.S.), Cardiology (K.T.M.), and Clinical Pharmacology K.T.M., C.M.S.), and Department of Biostatistics (P.G.A.); and Geriatric Research, Education and Clinical Center (W.A.R.), Veterans\u2019 Administration Tennessee Valley Health Care System, Nashville, Tenn; Research Triangle Institute Health Solutions (C..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia P.","family":"Chung","sequence":"additional","affiliation":[{"name":"From the Department of Preventive Medicine, Division of Pharmacoepidemiology (W.A.R., J.R.D.), Vanderbilt University School of Medicine; the Department of Medicine, Divisions of Rheumatology (C.C., C.M.S.), Cardiology (K.T.M.), and Clinical Pharmacology K.T.M., C.M.S.), and Department of Biostatistics (P.G.A.); and Geriatric Research, Education and Clinical Center (W.A.R.), Veterans\u2019 Administration Tennessee Valley Health Care System, Nashville, Tenn; Research Triangle Institute Health Solutions (C..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordi","family":"Castellsague","sequence":"additional","affiliation":[{"name":"From the Department of Preventive Medicine, Division of Pharmacoepidemiology (W.A.R., J.R.D.), Vanderbilt University School of Medicine; the Department of Medicine, Divisions of Rheumatology (C.C., C.M.S.), Cardiology (K.T.M.), and Clinical Pharmacology K.T.M., C.M.S.), and Department of Biostatistics (P.G.A.); and Geriatric Research, Education and Clinical Center (W.A.R.), Veterans\u2019 Administration Tennessee Valley Health Care System, Nashville, Tenn; Research Triangle Institute Health Solutions (C..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine T.","family":"Murray","sequence":"additional","affiliation":[{"name":"From the Department of Preventive Medicine, Division of Pharmacoepidemiology (W.A.R., J.R.D.), Vanderbilt University School of Medicine; the Department of Medicine, Divisions of Rheumatology (C.C., C.M.S.), Cardiology (K.T.M.), and Clinical Pharmacology K.T.M., C.M.S.), and Department of Biostatistics (P.G.A.); and Geriatric Research, Education and Clinical Center (W.A.R.), Veterans\u2019 Administration Tennessee Valley Health Care System, Nashville, Tenn; Research Triangle Institute Health Solutions (C..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. Michael","family":"Stein","sequence":"additional","affiliation":[{"name":"From the Department of Preventive Medicine, Division of Pharmacoepidemiology (W.A.R., J.R.D.), Vanderbilt University School of Medicine; the Department of Medicine, Divisions of Rheumatology (C.C., C.M.S.), Cardiology (K.T.M.), and Clinical Pharmacology K.T.M., C.M.S.), and Department of Biostatistics (P.G.A.); and Geriatric Research, Education and Clinical Center (W.A.R.), Veterans\u2019 Administration Tennessee Valley Health Care System, Nashville, Tenn; Research Triangle Institute Health Solutions (C..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James R.","family":"Daugherty","sequence":"additional","affiliation":[{"name":"From the Department of Preventive Medicine, Division of Pharmacoepidemiology (W.A.R., J.R.D.), Vanderbilt University School of Medicine; the Department of Medicine, Divisions of Rheumatology (C.C., C.M.S.), Cardiology (K.T.M.), and Clinical Pharmacology K.T.M., C.M.S.), and Department of Biostatistics (P.G.A.); and Geriatric Research, Education and Clinical Center (W.A.R.), Veterans\u2019 Administration Tennessee Valley Health Care System, Nashville, Tenn; Research Triangle Institute Health Solutions (C..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick G.","family":"Arbogast","sequence":"additional","affiliation":[{"name":"From the Department of Preventive Medicine, Division of Pharmacoepidemiology (W.A.R., J.R.D.), Vanderbilt University School of Medicine; the Department of Medicine, Divisions of Rheumatology (C.C., C.M.S.), Cardiology (K.T.M.), and Clinical Pharmacology K.T.M., C.M.S.), and Department of Biostatistics (P.G.A.); and Geriatric Research, Education and Clinical Center (W.A.R.), Veterans\u2019 Administration Tennessee Valley Health Care System, Nashville, Tenn; Research Triangle Institute Health Solutions (C..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis A.","family":"Garci\u0301a-Rodri\u0301guez","sequence":"additional","affiliation":[{"name":"From the Department of Preventive Medicine, Division of Pharmacoepidemiology (W.A.R., J.R.D.), Vanderbilt University School of Medicine; the Department of Medicine, Divisions of Rheumatology (C.C., C.M.S.), Cardiology (K.T.M.), and Clinical Pharmacology K.T.M., C.M.S.), and Department of Biostatistics (P.G.A.); and Geriatric Research, Education and Clinical Center (W.A.R.), Veterans\u2019 Administration Tennessee Valley Health Care System, Nashville, Tenn; Research Triangle Institute Health Solutions (C..."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"e_1_3_2_1_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200501063520101"},{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200501063520101"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200503173521134"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa071841"},{"key":"e_1_3_2_5_2","first-page":"1","volume":"00","year":"2008","unstructured":"Kearney PM, Baigent C, Godwin J, Halls H, Emberson JR, Patrono C. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ. 2008; 00: 1\u20137.","journal-title":"BMJ"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-7843.2006.pto_302.x"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.296.13.jrv60011"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.aje.a115198"},{"key":"e_1_3_2_9_2","unstructured":"Ruther M Pagan BA Rinkle V Yanck J. Program statistics: Medicare and Medicaid data book 1984. Health Care Financing Administration. 1986; June."},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1099-1557(199811\/12)7:6<389::AID-PDS380>3.0.CO;2-S"},{"key":"e_1_3_2_11_2","doi-asserted-by":"crossref","unstructured":"Garcia Rodriguez LA Perez-Gutthann S Jick S. The UK general practice research database. In: Strom B editor. Pharmacoepidemiology. III ed. New York: John Wiley & Sons LTD; 2000: 375\u2013385.","DOI":"10.1002\/0470842555.ch23"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.cir.0000132491.96623.04"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.2105\/AJPH.82.2.243"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1002\/sim.4780142404"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-8703(84)90558-1"},{"key":"e_1_3_2_16_2","first-page":"5.","year":"1976","unstructured":"World Health Organization Regional Office for Europe Copenhagen. Myocardial infarction community registers. WHO Public Health in Europe. 1976; 5.","journal-title":"WHO Public Health in Europe"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1067\/mhj.2001.116477"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1093\/geront\/28.5.672"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.aje.a117563"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1532-5415.1991.tb02872.x"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-114-4-257"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.159.2.161"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.aje.a010234"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)70270-1"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.58.12.1161"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2004.12.011"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annepidem.2003.10.002"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1159\/000015960"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1002\/pds.1518"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.gme.0000233494.28335.71"},{"key":"e_1_3_2_31_2","first-page":"30","volume":"19","year":"2007","unstructured":"Arbogast PG, Kaltenbach L, Ding H, Ray WA. Adjustment of multiple cardiovascular risk factors with a summary risk score. Epidemiol. 2007; 19: 30\u201337.","journal-title":"Epidemiol"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200011233432103"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(04)16894-3"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwg231"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)07370-1"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa003199"},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.289.3.305"},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.1093\/qjmed\/hch024"},{"key":"e_1_3_2_39_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.284.10.1247"},{"key":"e_1_3_2_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(06)69666-9"},{"key":"e_1_3_2_41_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.107.188515"},{"key":"e_1_3_2_42_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)12509-3"},{"key":"e_1_3_2_43_2","doi-asserted-by":"publisher","DOI":"10.1161\/circulationaha.106.616219"}],"container-title":["Circulation: Cardiovascular Quality and Outcomes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ahajournals.org\/doi\/full\/10.1161\/CIRCOUTCOMES.108.805689","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T02:34:14Z","timestamp":1715567654000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ahajournals.org\/doi\/10.1161\/CIRCOUTCOMES.108.805689"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,5]]},"references-count":43,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2009,5]]}},"alternative-id":["10.1161\/CIRCOUTCOMES.108.805689"],"URL":"https:\/\/doi.org\/10.1161\/circoutcomes.108.805689","relation":{},"ISSN":["1941-7713","1941-7705"],"issn-type":[{"value":"1941-7713","type":"print"},{"value":"1941-7705","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,5]]},"assertion":[{"value":"2009-05-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}